Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Its da Vinci Surgical System transforms the surgeon's natural hand movements outside the body into corresponding micro-movements inside the patient's body. The company's da Vinci Surgical System include surgeon's consoles, patient-side carts, 3-D vision systems, da Vinci skills simulators, da Vinci Xi integrated table motions, and Firefly fluorescence imaging products that enable surgeons to perform various surgical procedures, including gynecologic, urologic, general, cardiothoracic, and head and neck surgical procedures. It also manufactures EndoWrist instruments, such as forceps, scissors, electrocautery tools, scalpels, and other surgical tools, which incorporate wrist joints for natural dexterity for various surgical procedures. In addition, the company offers EndoWrist Stapler, a wristed stapling instrument for resection, transection, and creation of anastomoses; and EndoWrist One Vessel Sealers that are wristed single-use instruments for bipolar coagulation and mechanical transection of vessels up to 7mm in diameter and tissue bundles that fit in the jaws of the instrument. Further, it provides da Vinci Single-Site, a set of non-wristed and wristed instruments and accessories that allow da Vinci Surgical Systems to work through a single incision. Additionally, the company sells various accessories comprising sterile drapes for ensuring sterile field during surgery; and vision products that include replacement 3D stereo endoscopes, camera heads, light guides, and other items that facilitate use of the da Vinci Surgical System. It markets its products directly and through distributors in the United States, Europe, Asia, and internationally. The company was founded in 1995 and is headquartered in Sunnyvale, California.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone408-523-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.72 billion
Profitability
Miscellaneous
Employees5,527
Next Earnings Date7/18/2019 (Estimated)
OptionableOptionable
Intuitive Surgical (NASDAQ:ISRG) Frequently Asked Questions
What is Intuitive Surgical's stock symbol?
Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG."
When did Intuitive Surgical's stock split? How did Intuitive Surgical's stock split work?
Intuitive Surgical shares split on the morning of Friday, October 6th 2017. The 3-1 split was announced on Friday, August 11th 2017. The newly minted shares were distributed to shareholders after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Intuitive Surgical stock prior to the split would have 300 shares after the split.
How were Intuitive Surgical's earnings last quarter?
Intuitive Surgical, Inc. (NASDAQ:ISRG) released its earnings results on Thursday, April, 18th. The medical equipment provider reported $2.61 earnings per share for the quarter, missing the Zacks' consensus estimate of $2.70 by $0.09. The medical equipment provider earned $974 million during the quarter, compared to the consensus estimate of $975.27 million. Intuitive Surgical had a net margin of 29.78% and a return on equity of 17.33%. The firm's revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period last year, the company posted $2.44 earnings per share. View Intuitive Surgical's Earnings History.
When is Intuitive Surgical's next earnings date?
What price target have analysts set for ISRG?
17 brokers have issued 1-year price targets for Intuitive Surgical's stock. Their forecasts range from $375.00 to $635.00. On average, they expect Intuitive Surgical's stock price to reach $579.0625 in the next year. This suggests a possible upside of 19.3% from the stock's current price. View Analyst Price Targets for Intuitive Surgical.
What is the consensus analysts' recommendation for Intuitive Surgical?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intuitive Surgical in the last year. There are currently 1 sell rating, 3 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intuitive Surgical.
What are Wall Street analysts saying about Intuitive Surgical stock?
Here are some recent quotes from research analysts about Intuitive Surgical stock:
- 1. According to Zacks Investment Research, "Intuitive Surgical ended the first quarter on a dull note, with earnings and revenues lagging estimates. Contraction in the gross and operating margin is worrisome. Additionally, the da Vinci system is in the early stages of adoption in some of the markets outside the United States which is likely to impede placements. Intense competition in the global MedTech space is concerning as well. However, the flagship da Vinci procedures recorded solid growth in the quarter. In fact, management expects strong procedure growth in 2019. The company looks to accelerate its business in China, following the clearance of da Vinci Xi system. Sales outside the United States surged as well. Management is optimistic about the recent approvals for the Ion endoluminal system, IRIS augmented reality product and the da Vinci SP Surgical System. Meanwhile, the newly-formed Intuitive Foundation is expected to improve patient outcome." (4/24/2019)
- 2. BTIG Research analysts commented, "like we previewed, ISRG posted a healthy beat on procedures and system units placed but reported a slight miss on sales (increased leases) and opex came in near the top end of guidance, causing EPS to miss. We understand the benefits of offering several routes to system acquisition and the leases do not bother us. Getting more systems out there and surgeons trained before any significant competition makes sense. The continued increased spending is a concern. While we gather robotics is in the early days, the increased spending started a few years ago and what was initially discussed as a one- or two-year plan has become now at least a three- or four-year plan that seems like it may last a long time. With guidance revised to a 24-28% y/y increase vs the initial 20-28%, investors may pause." (4/21/2019)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating on shares of ISRG and maintain our PT of $620. ISRG reported 4Q18 results consistent with its preliminary announcement (1/9). ISRG delivered 19% procedure growth for 4Q18, largely driven by US general surgery and worldwide urology. ISRG reiterated its procedure growth guidance (13-17%), however we expect initial guidance to prove conservative as it has over the past several years. Management plans to increase opex by 20-28% in 2019, which comes as a surprise. We expect investors to have an initial negative reaction to the expected significant increase in spending, but we think the investments will fuel future top-line growth and accelerate ISRG’s pipeline." (1/25/2019)
- 4. Northland Securities analysts commented, "We are tweaking our models accordingly, and are introducing our FY20 numbers. Key Points Instrument & Accessory revs @ $539M vs. our estimate @ $535M. Systems revs @ $340M vs. our estimate @ $327M." (1/10/2019)
Has Intuitive Surgical been receiving favorable news coverage?
Media coverage about ISRG stock has been trending negative on Wednesday, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intuitive Surgical earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Who are some of Intuitive Surgical's key competitors?
Some companies that are related to Intuitive Surgical include Edwards Lifesciences (EW), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), Steris (STE), DEMANT A S/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Avanos Medical (AVNS), Inogen (INGN), Wound Management Technologies (WNDM), Establishment Labs (ESTA), RTI Surgical (RTIX) and ConforMIS (CFMS).
What other stocks do shareholders of Intuitive Surgical own?
Who are Intuitive Surgical's key executives?
Intuitive Surgical's management team includes the folowing people:
- Dr. Gary S. Guthart, CEO, Pres & Director (Age 53)
- Mr. Marshall L. Mohr, Exec. VP & CFO (Age 63)
- Mr. Salvatore J. Brogna, Exec. VP & COO (Age 64)
- Mr. David J. Rosa, Exec. VP & Chief Bus. Officer (Age 51)
- Dr. Myriam J. Curet McAdams, Exec. VP & Chief Medical Officer (Age 62)
Who are Intuitive Surgical's major shareholders?
Intuitive Surgical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.30%), FMR LLC (5.90%), Morgan Stanley (2.67%), Jennison Associates LLC (2.32%), Baillie Gifford & Co. (1.87%) and Janus Henderson Group PLC (1.55%). Company insiders that own Intuitive Surgical stock include Alan J Levy, Amal M Johnson, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical.
Which major investors are selling Intuitive Surgical stock?
ISRG stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Nomura Asset Management Co. Ltd., SG Americas Securities LLC, AQR Capital Management LLC, Morgan Stanley, American Century Companies Inc., First Trust Advisors LP and Janus Henderson Group PLC. Company insiders that have sold Intuitive Surgical company stock in the last year include Amal M Johnson, Craig H Barratt, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical.
Which major investors are buying Intuitive Surgical stock?
ISRG stock was bought by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Geode Capital Management LLC, GQG Partners LLC, GWM Advisors LLC, BlackRock Inc., Marshall Wace North America L.P. and Wellington Management Group LLP. View Insider Buying and Selling for Intuitive Surgical.
How do I buy shares of Intuitive Surgical?
Shares of ISRG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intuitive Surgical's stock price today?
One share of ISRG stock can currently be purchased for approximately $485.37.
How big of a company is Intuitive Surgical?
Intuitive Surgical has a market capitalization of $56.04 billion and generates $3.72 billion in revenue each year. The medical equipment provider earns $1.13 billion in net income (profit) each year or $9.49 on an earnings per share basis. Intuitive Surgical employs 5,527 workers across the globe.
What is Intuitive Surgical's official website?
How can I contact Intuitive Surgical?
Intuitive Surgical's mailing address is 1020 KIFER ROAD, SUNNYVALE CA, 94086. The medical equipment provider can be reached via phone at 408-523-2100 or via email at [email protected]
MarketBeat Community Rating for Intuitive Surgical (NASDAQ ISRG)
MarketBeat's community ratings are surveys of what our community members think about Intuitive Surgical and other stocks. Vote "Outperform" if you believe ISRG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISRG will underperform the S&P 500 over the long term. You may vote once every thirty days.
